

From: SMi Group Pharma <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 11/15/2016 9:48:19 AM
Subject: siRNA: 3 Pharmaceutical Companies to Watch in 2017

Innovations in siRNA Showcased by Quark, Novartis and AstraZeneca at RNA Therapeutics 2017

RNA Therapeutics 2017

8th Annual Conference: 22nd & 23rd February | Interactive Workshop: 21st February
Cophthorne Tara Hotel, Kensington, London, UK

Proudly sponsored by Lipocalyx

Register online at www.therapeutics-rna.com - £200 Earlybirds ends 30th November

"RNA therapeutics, including recent exciting advancements in RNA-based vaccines, have the potential to be game-changing technologies. This conference will bring together thought leaders from across the technology area..." - Jeffrey Ulmer, Head of Preclinical Research & Development, GSK

Dear Mr Tony Kester,

SMi Group are delighted to have **Quark Pharmaceuticals** present and provide exclusive **clinical trial results** at the 8th Annual **RNA Therapeutics** conference when it returns to Central London next February.

A recent report has named Quark Pharmaceuticals, a clinical-stage pharmaceutical company, as one of the top companies to watch in 2017. At the cutting edge of science, Quark builds upon the advancement of existing RNAi-based therapeutics, into siRNAs (small interfering RNAs), which can be designed based on the sequence information of virtually any gene, produced synthetically and used as drugs. Their most advanced programs focus on two drug candidates that are currently in late stage clinical trials for ophthalmic and kidney indications, QPI-1007 and QPI-1002.*

A siRNA EVENT SPOTLIGHT

Hear more from Quark in a keynote address on using siRNA to prevent acute kidney injury, presented by **Chief Medical Officer & President USA**, Shai Elrich. With a focus on targeting p53, the talk will discuss therapeutic approaches to prevent tissue damage and explore the possibilities of the natural distribution of siRNA to renal tissue. Study results will also be presented following a large Phase II clinical trial aimed at prevention of delayed graft function in patients receiving kidney transplants from deceased donors.

We also welcome the expertise of **Novartis** and **AstraZeneca** in the event spotlight on small interfering RNA's.

Nicole Meisner-Kober, **Senior Investigator, RNA Biology** from the Novartis Institutes for Biomedical Research, will offer progressive insight into subcellular targeting to directly improve the therapeutic index and thus clinical viability of siRNA therapeutics.

Sanyogitta Puri, **Associate Principle Scientist** from AstraZeneca, will explore formulation of siRNA versus plasmid in an address that will discuss the challenges of delivering small and large scale nucleic acids to cancers.

Scroll down for agenda highlights or [visit the website](#) to see a detailed conference programme and full speaker line-up.

HOW TO REGISTER

Secure your place by 30th November to take advantage of the **£200 earlybird**.

Register online at www.therapeutics-rna.com

Sponsorship enquires: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

Delegate enquires: Contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk

AGENDA HIGHLIGHTS - [Download brochure](#)

Day One - 22nd February 2017

- 8.30 **Registration & Coffee**
- 9.00 **Chairman's Opening Remarks**
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, **Imperial College London**
- 9.10 **RNA activation and its clinical application**
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, **Imperial College London**
- 9.50 **Collaborating to deliver macromolecules across biological barriers — a review of IMI COMPACT**
Steve Hood, Director, Scinovo, **GSK**
- 10.30 **Morning Coffee**
- 11.00 **Delivery of mRNA using the Viromer® system**
Steffen Panzner, Managing Director, **Lipocalyx**
- 11.40 **Therapeutic antisense oligonucleotides in oncology**
Mark Edbrooke, Senior Principal Scientist, **AstraZeneca**
- 12.20 **Networking Lunch**
- 1.30 **RNA Therapeutics Harnessing the Potential of Locked**
Bo Rode Hansen, Director, Technology and Partnered Discovery, **Santaris Pharma A/S**
- 2.10 **Sites of RNA silencing: Cell entry of exosomes as a novel paradigm for therapeutic RNA delivery**
Nicole meisner-kober, Senior Investigator, **Novartis Institutes for Biomedical Research**
- 2.50 **Afternoon Tea**
- 3.20 **RNAi and tumor microenvironment: pre-clinical and clinical evidence**
Amotz Shemi, CEO, **Silenseed**
- 4.00 **Individualized mRNA-based cancer immunotherapy**
Andreas Kuhn, Vice President RNA Biochemistry & Manufacturing, **BioNTech**
- 4.40 **Chairman's Closing Remarks and Close of Day One**
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, **Imperial College London**

Day Two - 23rd February 2017

- 8.30 **Registration & Coffee**
- 9.00 **Chairman's Opening Remarks**
Heinrich Haas, VP RNA Formulation and Drug Development , **BioNTech AG**
- 9.10 **Antisense in the fourth decade: Third generation antisense (3GA) fulfilling the promise**
Sudhir Agrawal, President & CEO, **Idera Pharmaceuticals**
- 9.50 **Interacting with the medicines regulator on RNAi therapies**
John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, **MHRA**
- 10.30 **Morning Coffee**
- 11.00 **Self-amplifying mRNA vaccines**
Jeffrey Ulmer, Head Preclinical R&D, **GSK**
- 11.40 **Nano-therapeutics; the best of all possible worlds?**
Andrew Miller, CSO, **KP Therapeutics Ltd**
- 12.20 **Networking Lunch**
- 1.30 **Intravenously injectable RNA Nanomedicines as cancer vaccines: case study with RNA-Lipoplexes**
Heinrich Haas, VP RNA Formulation and Drug Development , **BioNTech AG**
- 2.10 **The challenges and lessons learnt about the delivery of small and large nucleic acids to cancers**
Sanyogitta Puri, Associate Principal Scientist, **AstraZeneca**
- 2.50 **Afternoon Tea**
- 3.20 **Protecting the kidney: using siRNA targeting p53 to prevent and ameliorate acute kidney injury and delayed graft function**
Shai Erlich, VP, Pharmaceutical Development, **Quark Biotech Inc**
- 4.00 **Spherical Nucleic Acids: Structures for topical gene regulation**
David Giljohann, CEO, **Excure Inc.**
- 4.40 **Protecting your innovative products and methods: How to patent RNA therapeutics**
Mark Chapman, Partner, **Carpmaels & Ransford**
- 5.20 **Chairman's Closing Remarks and Close of Day Two**

Pre Conference Interactive Workshop - 21st February 2017

Precision Nano-therapeutics: Minding the Gap in Delivery from Preclinical Studies to Clinical Success

08.30 – 12.30 | Hosted by Professor Andrew David Miller, Professor of Organic Chemistry & Chemical Biology, CSO, King's College London, KP Therapeutics Ltd

Register online at www.therapeutics-rna.com

Source: <http://www.medreps.com/medical-sales-careers/5-pharmaceutical-companies-to-watch-in-2017/>.

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565

To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>